CytOSorb TreatMent Of Critically Ill PatientS Registry

Recruiting

• Conditions: Septic Shock; Acute Respiratory Distress Syndrome; Trauma; Rhabdomyolysis; Cardiogenic Shock; Pancreatitis; Acute on Chronic Liver Failure; Acute Liver Failure; Burns; Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Cytokine Release Syndrome (CRS)

• Registration Number: NCT05146336
• Lead Sponsor: CytoSorbents, Inc

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-11-23
• Last Update Posted: 2 September 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 3000

Inclusion Criteria

Inclusion Criteria:<br><br> 1. Planned OR actual CytoSorb® 300 mL device utilization<br><br> 2. Informed consent for prospective registry participation<br><br>Exclusion Criteria:<br><br> 1. Use of the CytoSorb® 300 mL device for antithrombotic removal only<br><br> 2. Intraoperative use of CytoSorb® 300 mL device during cardiac surgery only<br><br> 3. The occurrence of a complication or other medically justified circumstance that<br> arises after written informed consent has been obtained from the patient and before<br> or during the planned therapy and as a result of which the use of CytoSorb® 300 mL<br> Adsorber is contraindicated or no longer appropriate.

Exclusion Criteria

Not provided

Study & Design

• Study Type: Observational [Patient Registry]
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ICU mortality;In-hospital mortality